Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration.
Keywords: direct-acting antivirals; hepatitis C virus; mathematical modeling; response-guided therapy; time to cure.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.